New US Warnings Issued Over Weight-Loss Drugs and Vision Loss Risks

The US Food and Drug Administration has mandated new warnings for weight-loss and diabetes drugs belonging to the glucagon-like peptide-1 receptor agonist class.

The updated labels address the potential risk of a rare condition known as NAION, which is caused by restricted blood flow to the optic nerve and can lead to permanent vision loss.

The decision follows an extensive analysis of more than 125 clinical trials. Data indicated an incidence rate of six cases per 100,000 users annually, a figure considered higher than that observed in patients using alternative treatments.

Health authorities have advised patients to seek immediate medical attention if they experience blurred vision or any loss of their visual field while using these medications.